好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Natural History and Phenotypic Spectrum of LGMD-D1: Implications for Clinical Trials
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (9:00 AM-5:00 PM)
380

We sought to delineate the full phenotypic spectrum and characterize the natural history of limb girdle muscular dystrophy-D1 (LGMD-D1) through a combination of systematic literature review, retrospective chart review, and a cross sectional observational study with a subset of longitudinal assessments.

LGMD-D1 is an ultra-rare neuromuscular disorder due to dominant mutations in the HSP-40 co-chaperone DNAJB6. Promising therapeutic strategies are starting to emerge, accelerating the need for clinical trial readiness.

We extracted demographics and age at clinical events of interest contributing to LGMD-D1 disease burden, such as cardiac, respiratory, and swallowing abnormalities, as well as loss of ambulation from systematically identified case reports, case series, and LGMD-D1 patient charts. We determined the frequency of events and used survival analyses to estimate median time from onset to clinical events. When available, manual muscle testing and quantitative dynamometry were utilized to estimate muscle specific rates of strength decline. Retrospective analyses were complemented with a cross sectional observational study including the Measure of Activity Limitations (ACTIVLIM) and a customized LGMD-D1 questionnaire, cataloging patients’ ages at clinical events of interest. Longitudinal assessments were completed 1.5 years apart in a subset of patients. All data was assessed for differences between males and females, proximal and distal predominant phenotypes, as well as genotype specific changes.

At time of submission, 115 LGMD-D1 patients were included. This study is the largest description of LGMD-D1 patients to date.  Overall, this data highlights key genotype - phenotype differences among LGMD-D1 patients, including age of disease onset, progression to loss of ambulation, and weakness patterns.

Future clinical trials will need to account for variability in these key phenotypic features when selecting outcome measures and enrolling patients.
Authors/Disclosures
Conrad Weihl, MD, PhD (Washington University in St. Louis)
PRESENTER
Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Casma therapeutics. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abata. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acceleron. Dr. Weihl has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Wilson Elser Moskowitz Edelman & Dicker LLP.
Andrew R. Findlay, MD (Washington University) Dr. Findlay has received personal compensation in the range of $0-$499 for serving as a Consultant for Rivervest. Dr. Findlay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. Findlay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atheneum. Dr. Findlay has received personal compensation in the range of $0-$499 for serving as a Consultant for TriangleInsights. The institution of Dr. Findlay has received research support from NIH. The institution of Dr. Findlay has received research support from American Society for Gene and Cell Therapy. The institution of Dr. Findlay has received research support from 好色先生. The institution of Dr. Findlay has received research support from The LGMD-1D DNAJB6 Foundation and International Registry. The institution of Dr. Findlay has received research support from Children's Discovery Institute of Washington University and St. Louis Children's Hospital.
No disclosure on file
No disclosure on file
No disclosure on file